Neoadjuvant anti-PD1, nivolumab, in early stage resectable non-small-cell lung cancer.

IF 42.1 1区 医学 Q1 ONCOLOGY Journal of Clinical Oncology Pub Date : 2016-05-20 DOI:10.1200/JCO.2016.34.15_SUPPL.E20005
P. Forde, Kellie N. Smith, J. Chaft, M. Hellmann, T. Merghoub, J. Wolchok, Stephen C. Yang, R. Battafarano, E. Gabrielson, C. Georgiades, G. Rosner, V. Anagnostou, V. Velculescu, S. Topalian, D. Pardoll, J. Brahmer
{"title":"Neoadjuvant anti-PD1, nivolumab, in early stage resectable non-small-cell lung cancer.","authors":"P. Forde, Kellie N. Smith, J. Chaft, M. Hellmann, T. Merghoub, J. Wolchok, Stephen C. Yang, R. Battafarano, E. Gabrielson, C. Georgiades, G. Rosner, V. Anagnostou, V. Velculescu, S. Topalian, D. Pardoll, J. Brahmer","doi":"10.1200/JCO.2016.34.15_SUPPL.E20005","DOIUrl":null,"url":null,"abstract":"e20005Background: Nivolumab is an anti-PD1 immune checkpoint blocker which has demonstrated durable responses and improved survival vs. second-line chemotherapy in metastatic non-small-cell lung ca...","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":"34 1","pages":""},"PeriodicalIF":42.1000,"publicationDate":"2016-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"13","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1200/JCO.2016.34.15_SUPPL.E20005","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 13

Abstract

e20005Background: Nivolumab is an anti-PD1 immune checkpoint blocker which has demonstrated durable responses and improved survival vs. second-line chemotherapy in metastatic non-small-cell lung ca...
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
新辅助抗pd1,纳武单抗,在早期可切除的非小细胞肺癌。
e20005背景:Nivolumab是一种抗pd1免疫检查点阻断剂,与二线化疗相比,在转移性非小细胞肺癌中表现出持久的反应和提高的生存率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Clinical Oncology
Journal of Clinical Oncology 医学-肿瘤学
CiteScore
41.20
自引率
2.20%
发文量
8215
审稿时长
2 months
期刊介绍: The Journal of Clinical Oncology serves its readers as the single most credible, authoritative resource for disseminating significant clinical oncology research. In print and in electronic format, JCO strives to publish the highest quality articles dedicated to clinical research. Original Reports remain the focus of JCO, but this scientific communication is enhanced by appropriately selected Editorials, Commentaries, Reviews, and other work that relate to the care of patients with cancer.
期刊最新文献
Comparative Analysis of Intracranial Response Assessment Criteria in Patients With Melanoma Brain Metastases Treated With Combination Nivolumab + Ipilimumab in CheckMate 204. Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703. Adjuvant Dose-Dense Chemotherapy in Hormone Receptor-Positive Breast Cancer. Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer-The Phase III MECCA Trial. Cardiac Dysfunction Among Breast Cancer Survivors: Role of Cardiotoxic Therapy and Cardiovascular Risk Factors.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1